Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

US6316504A · kind A · utility

Assignees

• Technion Research & Development Foundation Limited · IL
• TEVA PHARMACEUTICAL INDUSTRIES, LTD. · IL

Inventors

• Moussa B. H. Youdim · Rockville, US
• John P. M. Finberg · Rekhasim, IL
• Ruth Levy · Skippack, US
• Jeffrey Sterling · Jerusalem, IL
• David Lerner · Akron, US
• Haim Yellin · Ramat Gan, IL
• Alex Veinberg · Rehovot, IL

Key dates

• Filing date: Nov 16, 1998
• Grant date: Nov 13, 2001
• Expiry date: Nov 16, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.